Legends): 2967 20 regional/national centres to provide information relevant to patient management. By 36 providing viable workflows for both the Sanger and MinION sequencing platforms, which 37 vary greatly in the infrastructure and expertise required, we demonstrate that MinION 38 sequencing is a viable method for HBV genotyping in resource-limited settings. These 39 workflows could also be applied to sequencing of other blood borne DNA viruses and 40 bacterial pathogens. 41 Abstract word count: 230 42 43 44
Abstract

22
In order to achieve the commitment made by the World Health Organisation to eliminate 23 viral hepatitis by 2030, it is essential that clinicians can obtain basic sequencing data for 24 hepatitis B virus (HBV) infected patients. While accurate diagnosis of HBV is achievable in 25 most clinical settings, genotyping and identification of resistance-associated substitutions 26 (RAS) present a practical challenge in regions with limited healthcare and biotechnology 27 infrastructure. Here we outline two workflows for generating clinically relevant HBV 28 sequence data directly from dried serum spot (DSS) cards without DNA extraction using 29 either Sanger, or the portable MinION sequencing platforms. Data obtained from the two 30 platforms were highly consistent and allowed determination of HBV genotype and RAS. This 31 is the first demonstration of MinION sequencing from DSS, illustrating the broad utility of 32 this sequencing technology. We demonstrated the clinical application of this technology 33 using sera sampled on DSS cards obtained from both Iraq and Brazil. The sample stability 34 provided by DSS cards, combined with the rapid PCR and sequencing protocols will enable 35 Introduction 45
Hepatitis B virus (HBV) infects 257 million people worldwide and causes 887,000 deaths per 46
year, many due to hepatocellular carcinoma (HCC) (1). A recent editorial in Nature described 47 HBV as neglected, particularly in Sub-Saharan Africa, where around 6% of the population are 48 infected and only one-tenth of children are vaccinated (2). There is an urgent need for 49 screening and surveillance tools to assess HBV in low and middle-income countries (3). HBV 50 displays a higher degree of diversity relative to other DNA viruses due to a complex and 51 error prone replication cycle involving RNA intermediates, as such it has a mutation rate of 52 around 1.4-3.2 x 10 -5 mutations/site/year (4). There are many well-characterised mutations 53 across the HBV genome, conferring resistance to therapy or an increase in replication 54 efficiency (polymerase), immune and diagnostic test escape (S/pre-core), or an increase in 55 tumorigenesis (reviewed in (5)). 56
Next generation sequencing (NGS) enables the study of a population of viral genomes within 57 a single patient, as opposed to Sanger sequencing, which will theoretically provide a 58 "consensus" sequence of the most abundant template. NGS platforms such as those 59 established by Illumina rely on the use of short reads (max 250bp) which are assembled to 60 from a contiguous sequence. Third generation sequencing platforms such as the Oxford 61 Nanopore (ONT) MinION enable sequencing with theoretically no upper limit on read 62 length, meaning entire viral genes or genomes can be sequenced in a single read. The 63
MinION sequencer is also extremely portable and can be powered through a laptop, 64 removing the need for a continuous power supply and enabling sequencing in locations 65 without access to conventional lab facilities. The portable aspect of MinION sequencing has 66 already been demonstrated to great effect during the Ebola outbreak in West Africa (6), and 67 in tracking the spread of Zika virus in Brazil (7) . Field application of the MinION platform has 68 been enhanced with recent advances including improved "R9.4" flow cells with increased 69 accuracy and software such as Nanopolish (8) different primer pairs was also tested by serially diluting a high viral titre sample (1.2 x 10 7 123 IU/mL) logarithmically down to 1.2 x 10 1 IU/mL. 124 Initially a well cited primer set (F1 and R1) generating a short amplicon in a conserved 125 genomic sequence towards the end of the S gene (9) was used to probe the maximum 126 sensitivity of direct PCR from serum and DSS derived from the control Nottingham cohort. 127
This primer site is also situated within the RT domain of the polymerase gene, allowing for 128 genotyping and determination of some RAS. A second widely used primer set (F2, F3, R2 and 129 R3; (10)) was subsequently tested to generate larger amplicons and thus greater DNA 130 sequence information. The sets were further tested in a variety of combinations to generate 131 amplicons of intermediate length overlapping in genomic coverage. 132
Sanger sequencing and phylogeny: PCR-positive products were diluted 1:10 with water and 133 couriered at ambient temperature for sequencing by a commercial service (Source 134 Bioscience, Nottingham, UK). Short products were sequenced with F1 primer only, and 135 longer F1/R3 and F3/R1 products were sequenced with both F1 and R1 primers. These reads 136 were assembled to produce a complete contiguous sequence covering PreS2/S. Sequences 137 used for phylogenetic analysis were aligned using MUSCLE in MEGA X (11, 12), and 138 maximum likelihood trees constructed using a General Time Reversible model in MEGA X. 139
Samples containing deletions were excluded from the tree. Sequences were deposited in 140
GenBank under accession numbers MK517481 -MK517524. 141
MinION sequencing library preparation: Three high titre (>10 7 IU/mL) samples from both 142
Brazil and Iraq cohorts were selected for sequence analysis. Barcoded samples were 143 prepared for MinION sequencing using a two stage PCR approach and the SQK-LWB001 144 library preparation kit. First round PCR was carried out as above, using 25 µL Hemo KlenTaq 145 reactions with 3 mm 2 punches from DSS. F4 and R4 primers were used as specified in table  146 1. From this reaction, 1 µL of product was then used as the template for a 50 µl PCR 147 containing 25 µL 2x LongAmp HotStart Taq master mix, 1.5 µL of barcoded primer mix 148 (supplied by ONT) and 22.5 µL nuclease free water. Products were then prepared according 149 to the SQK-LWB001 kit protocol. Briefly, PCR products were bound to AMPure XP beads 150 (Beckman Coulter) and washed with 70 % ethanol, before eluting in 10 µL 10mM Tris-HCl 151 (pH 8.0) with 50mM NaCl. Cleaned products were then quantified by Qubit using the dsDNA 152 high sensitivity kit (Thermo Fisher). Based on the method developed by Quick et al. (7), 153 amplicons were pooled to achieve a total of 0.3 pM input DNA per MinION flow cell, 154 therefore for 1.3 kb amplicons this equates to ~260 ng total DNA. Following ligation of rapid 155 sequencing adapters, the library was run for 48hrs on a MinION Mk II through a computer 156 running MinKNOW 1.10.16 in Microsoft Windows followed by basecalling using Albacore 157 2.2.2. Adapter-trimmed sequences were uploaded to the NCBI Sequence Read Archive 158 under project ID PRJNA521740. 159
MinION sequencing analysis: Basecalled reads were trimmed using Porechop 0.2.3 using 160 high stringency settings (--discard_middle and --require_two_barcodes) and retained when 161
Porechop and Albacore barcode aligners were in agreement. NanoPlot was used to inspect 162 read quality and length, and reads were filtered based on length using NanoFilt (13) to a 163 minimum length of 1200 and maximum length of 1300 nucleotides. 164
Processed reads were used as the input for Canu (v1.7.1) (14), a de novo genome assembler 165 optimised for use with long, error-prone reads. The same reads were subsequently aligned 166 using Minimap2 (15) to their respective consensus sequences generated by Canu and 167 manually inspected using IGV (Broad Institute) to ensure complete coverage and to inspect 168 for significant structural variants. Alignments were further processed using Nanopolish 169 v0.10.2 (8), using the Variants module and the --fix-homopolymers function to generate a 170 corrected consensus sequence. A full description of the bioinformatics workflow used is 171 included as supplementary data. As validation Sanger sequences were produced by 172 sequencing amplicons with both F1 and R1 primers, these were used as the "gold standard". 173
Canu and Nanopolish consensus sequences were aligned with their respective Sanger contig 174 using MEGA. 175
Genotyping and variant calling: For both Sanger and MinION sequence data genotypes 176
were determined using the web-based tool HBV geno2pheno (16). Known HBV treatment 177 resistance and immune escape variants were screened using the hepatitis B virus database 178 (HBVdb (17)). Mutations against the genotype consensus reference sequences used in 179 geno2pheno that were not flagged as clinically significant are provided in supplementary 180 Initially we assessed three previously described primer sets for amplification of regions of 189 the HBV genome using Hemo KlenTaq polymerase. A known HBV-positive serum sample 190 with viral load >10 7 IU/mL was diluted 10-fold and spotted onto DSS cards. Using direct PCR 191 of punched-out discs from these cards, HBV amplicons were obtained using all the primer 192 pairs analysed (table 2) . Amplification of the smallest product, using primers F1 and R1, was 193 the most sensitive approach, amplifying a product from a sample containing as little as 1 x 194 10 3 IU/mL. Larger products (over 700 bp) were achieved using these primers in combination 195 with the F3 and R3 primers down to 10 4 IU/mL. Subsequent investigation demonstrated that 196 PCR amplification using Phusion Blood Direct polymerase allowed for increased sensitivity 197 when amplifying small products, down to 600 IU/mL but gave little improvement in 198 sensitivity when amplifying larger products (data not shown). The 27 successfully genotyped samples divided into subtypes as follows: seven A1, two A2, 208 one B1, two D1, two D1, two D2, nine D3, one F1 and three F2 (table 3) . 209
It was not clear why three of the samples could not be amplified using the F1/R1 primer 210 pair, but it is likely due in part to lower viral load as all three had viral loads of ~1 x 10 3 -1 x 211 10 4 IU/mL (table 3) . As the genotypes of these samples had not been previously determined 212 it was not possible to confirm whether the primer pair had a lower sensitivity for some 213 genotypes. 214
Successful amplification of the larger products using primer pairs F1/R3 and F3/R1 appeared 215 to be associated with viral load (table 3 ). Both primer pairs were able to generate amplicons 216 from samples of viral load >10 6 IU/mL. F3/R1 displayed a higher sensitivity for genotype D 217 samples as amplicons were achieved for samples Br13 and Br16 (viral loads 5.99 x10 5 and 218 2.58 x10 5 IU/mL, respectively), although no amplicon was obtained for the higher viral load 219 sample Br12 (9.41 x 10 5 IU/mL). 220
Genotyping and RAS characterisation 221 222
The 2.58 x 10 2 IU/mL), or why three high viral load samples could not be amplified (2.28 x 10 8 , 242
1.60 x 10 7 and 1.42 x 10 7 IU/mL). 243
While no RT RAS were detected, three samples contained known sAg immune escape 244 mutants, demonstrating that this process can provide clinically relevant sequence 245 information from poorly characterised samples. 246
Samples from both cohorts demonstrated clustering by genotype when plotted on a 247 maximum likelihood tree with respective genotype references from GenBank (figure 3). 248
MinION sequencing direct from DSS 249 250
Having obtained clinically relevant sequence data by Sanger sequencing from DSS, we 251 investigated whether comparable data could be obtained using MinION sequencing. Three 252 samples each were selected from the Brazilian and Iraqi cohorts (Br1, Br2 and Br3; Iq2, Iq3 253 and Iq4), that had been successfully amplified with all three primer pairs. Amplicons of 254 1,274 bp were generated using primers F4 and R4, which were analysed in parallel by 255 Nanopore sequencing. A total of 185,349 raw reads were obtained for the 6 samples, 256 ranging from 23869 to 41392 per barcode. Following adapter trimming and further filtering 257 of erroneously long and short reads these counts ranged from 7676 to 11832 per barcode 258 (table 5) HBV has the capacity to exist in a host as a population of closely related viruses (18). While 289 not displaying the extreme variability associated with RNA viruses, error-prone reverse 290 transcription facilitates rapid adaptation to the host environment. As a consequence, 291 resistance to antiviral therapies is common. Methods to both genotype and characterise 292 RAS in parts of the world without access to conventional laboratory and sequencing facilities 293 would be clinically beneficial. These techniques may become increasingly important in 294 places such as sub-Saharan Africa, where antiretroviral programmes are in place for HIV 295 treatment but HBV prevalence and development of resistance to drugs such as lamivudine is 296 not accounted for (19, 20) . As HIV mortality decreases and life expectancy increases, the 297 development of chronic liver disease due to HBV infection will be of increasing concern. 298 We have demonstrated that clinically useful HBV sequence data can be obtained from DSS, 299 with a lower-limit of detection of approximately 600 IU/mL, using a relatively cost-effective 300 method that requires no cold chain. Several of the RAS detected in this cohort are clinically 301 significant. The Y100C mutant in the S region of HBsAg has been linked to false negative/low 302 HBsAg tests (21), and appears to be common in our Brazilian cohort, being present in 5/10 303 genotype A samples. More significantly, as it targets the RT domain of Pol, this method 304 allows characterisation of drug resistance markers, which is potentially valuable in countries 305 where prescription of drugs known to select for HBV resistance is common. The V173L, 306 L180M and M204V RAS detected in the polymerase gene indicate resistance to the 307 nucleoside analogues lamivudine and entecavir. 308
Although our original methodology removed the need for a cold chain and required only 309 basic or mobile laboratory facilities, a Sanger sequencer (or access to a sequencer-equipped 310 laboratory to where DSS/amplicons can be shipped) was still required. We therefore aimed 311 to combine our DSS method with nanopore sequencing, increasing portability and to 312 provide a method that can be rapidly deployed in resource-poor settings. 313 NGS datasets were successfully generated for all of the six of the samples tested. All 314 samples demonstrated the characteristic error profile associated with nanopore 315 sequencing, with frequent indels in homopolymers of 3 bases or more (22). In all cases 316 these miscalls were removed using Nanopolish. These errors, which occur when voltage 317 signal remains constant across homopolymer templates passing through the nanopore, will 318 potentially become less of an issue with improved software interpolation or the 319 development of new protein nanopores. In all cases the data was sufficiently accurate that 320 the assembly generated by Canu, including indels, could be used to reliably and quickly 321 genotype without any further processing, and with subsequent processing in Nanopolish 322 produced sequences that were 100% identical to the sequence reads generated by Sanger 323 sequencing. This method is therefore of use in situations where Sanger sequencing is 324 unavailable and illustrates the utility of the MinION as a portable sequencer to determine 325 the consensus of a virus population. 326
Sanger sequencing of HBV enables characterisation of a consensus sequence of theoretically 327 the most abundant nucleotide at each position in a viral sequence within a sample. 328
Inspection of minor peaks on the electropherogram allows detection of minor sequence 329 variants, down to a prevalence of around 20%, dependent on sample quality. As has been 330 previously shown with HBV, next generation sequencing approaches allow characterisation 331 of minor variants at a lower threshold (23-25). This information is potentially clinically 332 useful, enabling earlier detection of resistant viruses, informing selection of appropriate 333 treatment regimens. Accurately determining these minor variants with NGS is 334 methodologically difficult, as low concentrations of viral template often necessitate the use 335 of PCR before sequencing. This may introduce bias from a range of sources. A recent 336 investigation (26) suggested that if PCR primers are well designed an amplicon sequencing 337 approach can be as reliable as unbiased metagenomic sequencing. However, the authors 338 highlighted that in its current level of development, MinION sequencing is not appropriate 339 for discovering novel, low-level intra-host sequence variants due to the high false-discovery 340 rate. In our data, we applied a conservative variant calling approach by aligning all sequence 341 reads to the consensus followed by variant calling using Nanopolish. 342
Sequencing HIV from dried blood spots using 454 pyrosequencing previously showed almost 343 complete concordance with Sanger (27), but discrepancies appeared when characterising 344 minor variants, particularly in low titre samples (28) . Further experiments using more 345 appropriate variant calling workflows, and a side-by-side comparison of DSS, direct serum 346 and DNA extract would be required to study the potential effect of storing DSS samples on 347 measures of diversity. The majority of candidate variants in our data were filtered out using 348
Nanopolish, suggesting they could be false-positives caused by sequencer error. A variant 349 that remained unfiltered was present in 5 of 6 samples (and therefore was not genotype 350 specific), the mutation, P217L in S has previously been linked to diagnostic escape (29). The 351 other minor variant, L109P in S, was present in a single sample (Iq1), and has been linked to 352 an increase in hydrophobicity (30), but the significance of this phenotype has not been 353
determined. 354
The MinION sequencing protocol described here followed the manufacturer's 355 recommended protocol, using the standard 48-hour script in order to maximise read depth. 356
As demonstrated elsewhere (31), an alternative approach is to run the MinION for a shorter 357 amount of time, flush the flow cell and add different samples. Larger barcode kits (up to 96) 358 and custom barcodes can also be used. With this assay, setup can be adjusted to favour 359 either assay throughput or read depth, prioritizing rapid consensus sequence generation or 360 interrogation of intra-sample diversity. The metrics produced by the sequencer as shown in 361 figure 4 can aid in this optimisation and be used to determine the optimum timepoint to 362 stop a sequencing run and add more samples, in order to ensure efficient use of resources. 363
Based on current prices, and after an initial outlay on basic lab equipment (PCR machine, 364 pipettes), we estimate that accurate sequence data with the MinION could be obtained for 365 as little as 20 GBP per sample. In comparison, a single Sanger read across the region studied 366 in this paper will cost ~4 GBP, with larger regions requiring at least 2 reads for complete 367 coverage. 368 369 One limitation of this method is the amount of template input required for successful 370 amplification; obtaining long amplicons (in this case ~1247 bp) suitable for MinION 371 sequencing required serum spots generated from samples with viral titre of at least 10 6 -10 7 372 IU/mL. As expected, successful amplification was inversely correlated with viral load, making 373 assays which involve amplifying all or most of S in a single amplicon only applicable to high 374 titre samples. The combination of F4/R4 primers was chosen to take advantage of the long 375 reads available with MinION sequencing. Increased sensitivity could be achieved using a 376 PCR-tiling approach of two or more amplicons that are pooled before sequencing (as 377 demonstrated with the much larger Zika genome (7)), or by scaling up reaction mixtures and 378 using more DSS per reaction. 379
The workflow described in figure 6 is intended as a starting point for a diagnostic workflow, 380 but, as indicated above, this method can be modified at each point to address specific 381 clinical questions with different pathogens. In our application, dried serum spots were 382 studied based on available samples, but the modified Taq enzymes used are suitable for use 383 with whole blood, plasma or serum added directly to the PCR reaction. There is also the 384 potential to apply this approach to other viruses where high-throughput testing is desired, 385 for example improving existing workflows for cytomegalovirus (32) . 386
387
In summary, we describe two approaches for rapid genotyping and RAS detection in 388 hepatitis B virus, which are applicable in resource-limited settings and require little existing 389 infrastructure. The results presented here demonstrate the utility of direct PCR enzymes 390 and DSS together in a clinical context. To our knowledge this has not been previously 391
described. We have also demonstrated, for the first time, that nanopore sequencing can be 392 applied directly to samples amplified from serum spots. Reliable sequence data was 393 generated using the MinION sequencer, removing the need for reliance on laboratory 394 infrastructure. Although accurate consensus sequences can be generated, it is likely that 395 both the software and hardware associated with nanopore sequencing will require 396 improvement before this method will find routine use for detecting minor variants within a 397 virus population. Tables   417  418  419  420 Primer name 513  514  515  516  517  518  519  520  521  522  523  524  525  526  527  528  529  530  531  532  533  534  535  536  537  538  539  540  541  542  543  544  545  546  547  548  549  550  551  552  ID  Genotype  sAg mutants  Pol mutants   Br1  A1  Y100C, S207N  D7N, N122H, M129L, W153R, V163I, I253V, V278I, M336L, V341P   Br2  A1  Y100C, S207N  D7N, N122H, M129L, W153R, V163I, I253V, V278I, M336L   Br3  D2  T118A, E164D, I195M  Y45H, H126R, V173L, H126R, V173L, L180M, M204V, K270R   Br4  A1  G44E, Y100C, S207N  N122H, M129L, W153R, V163I, I253V, V278I, M336L   Br5  D3  T127P  F122L, Q130P, Y135S   Br6  D3  T127P F122L, Q130P, Y135S, S176R Br7 A1 Y100C S117P, N122H, M129L, W153R, V163I
Br8 D3 I110L, G112N, S114P, T125M N118T, R120K, I121F, F122A, N123D, Q130P, Y135N, S176R Br9 F2 N123D, M129L, S137T, V173L Br10 A2 D7A, I53V Br11 F2 N123D, M129L, S137T, S176R Br30  D3  G119A, C124S, T127P, Q129E, Y143N, P135T,  G145E, T148S, I152L, P153T L115V, F122L, T128S, Q130P, L132Q, D134H, Y135S, S137*, V142E, S143Y, H156Q, H160S, P161H, S176R Iq1 D1 T127P S109P, Y135S   Iq2  D1  T127P  Y135S   Iq3  D1  T127P  Y135S   Iq4  D1  T127P  Y135S   Iq5  D1  T127P  M129L, Y135S, S176R   Iq6  D1  Q101H, P120S, T127P  T128I, M129L, Y135S, S176R   Iq7  D1  P120S, T127P  T128I, Y135S, S176R   Iq8  D3  T127P  Y135S   Iq9  D1  S114A, T125M, G145R  F122R, H124N, Q130P, N131D, R153Q, S176R   Iq10  D1  Q101H, T127P, Y134H, T140I  M129L, Y135S, V142A, S176R   Iq11  D1  T127P Y135S, S176R The ML tree was inferred using a general time reversible model within MEGA X (11). 698
Supplementary
Statistical robustness was assessed using bootstrap resampling of 1,000 pseudoreplicates, 699 and the tree with the highest log-likelihood is shown. Nottingham is provided by a commercial service with sample collection and over-night 719
